MedPath

Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)

Recruiting
Conditions
Brain Injuries, Traumatic
Registration Number
NCT04893837
Lead Sponsor
University of Alabama at Birmingham
Brief Summary

MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.

Detailed Description

MOBI-1 is a single-arm, multi-center derivation / validation study that will evaluate the use of the Infrascanner for monitoring traumatic intracranial hematomas. All patients will receive standard care plus hourly infrascanner assessments. This study will test the hypotheses that:

1. The Infrascanner has sufficient diagnostic performance to detect the expansion of intracranial hematomas

2. Patients who have expanding intracranial hematomas will be identified faster when monitored with hourly infrascanner assessments compared to standard care alone

3. Clinical / research staff will be able to attain all data points and relay the assessments to the medical team.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
440
Inclusion Criteria
  1. Age 15 or older
  2. Admission CT Scan shows intracranial hemorrhage
  3. Glasgow Coma Scale less than 15
  4. Neurosurgery service determines initial care is nonoperative
  5. Admitted for observation for TBI, to either step-down unit or intensive care unit
Exclusion Criteria
  1. Inability to provide informed consent or lack of a legally authorized representative (LAR)
  2. Admitted and observed for >2 hours prior to screening (i.e., has already received second neurological check)
  3. Other injuries deemed non-survivable
  4. Diagnosed with hemorrhagic shock or receives a large volume transfusion (>3 units of any blood product within any 1 hour)
  5. Planned surgical interventions/ procedures during study period (before the second CT scan)
  6. Known prisoner

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Diagnostic performance of the infrascannerMonth 24

Number of participants whose Infrascan results were accurate

Secondary Outcome Measures
NameTimeMethod
Time to detection of an enlarging hematoma0-12 hours

Difference in time to detection of hematoma enlargement between Infrascan and second CT across the cohort

Trial Locations

Locations (2)

UAB Hospital

🇺🇸

Birmingham, Alabama, United States

University of Arizona

🇺🇸

Tucson, Arizona, United States

UAB Hospital
🇺🇸Birmingham, Alabama, United States
Jan O Jansen, MBBS, PhD
Contact
205-975-2393
jjansen@uabmc.edu
Shannon W Stephens
Contact
205-934-5890
swstephens@uabmc.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.